| Detected | Trial | Change |
|---|---|---|
| 2026-08-07 | NCT07317934 Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related… |
Primary endpoint(s) modified |
| 2026-08-07 | NCT07317934 Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related… |
Enrollment increased: 332 -> 388 participants |
| 2026-08-07 | NCT07317934 Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related… |
Trial sites expanded: 31 -> 36 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07317934 | Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related… | Neovascular Age-Related Macular Degeneration (nAMD) | Recruiting |
| NCT07054632 | Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65… | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Active, Not Recruiting |
| Phase 2 | |||
| NCT06196840 | Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related… | Neovascular Age-Related Macular Degeneration | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06212297 | Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy | Inherited Retinal Dystrophy | Active, Not Recruiting |
| Phase 1 | |||
| NCT06198413 | LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-Related Macular Degeneration | Active, Not Recruiting |
| NCT06196827 | Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65… | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Active, Not Recruiting |